Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: VLAD who wrote (19955)	3/21/1999 9:24:00 PM
From: Mkilloran	Read Replies (2) \| Respond to of 23519

vlad...the future of Vivus is looking much brighter... hope to hear about progress in Japan, additional non ED meds, Gene Therapy, Female SD progress with projected FDA testing time frames, etc Spain still has time to get license approval before the end of this month Italy to follow early next qtr.. Spring time for VVUS ..... Astra/Zeneca merger in early April...USA partner for Vivus will be announced in the 2nd qtr IMO $6-8 trading range is next short term target..... Double digits in the 2nd qtr....... Expect WallStreet Analyst upgrades in a few weeks with a good conf call

To: VLAD who wrote (19955)	3/21/1999 9:47:00 PM
From: wvalx	Read Replies (1) \| Respond to of 23519

LFW R(esigns) There's my guess...will you tell us if we're right? My second guess is: VVUS A(dded) T(o) DJIA that would probably get institutional investors onboard go VVUS!